AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Tealwood Asset Management Inc.

Tealwood Asset Management Inc. reduced its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 1.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 37,120 shares of the company’s stock after selling 540 shares during the period. AstraZeneca makes up approximately 1.3% of Tealwood Asset Management Inc.’s investment portfolio, making the stock its 11th biggest holding. Tealwood Asset Management Inc.’s holdings in AstraZeneca were worth $2,892,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. GHP Investment Advisors Inc. acquired a new stake in shares of AstraZeneca during the second quarter worth $26,000. Able Wealth Management LLC acquired a new stake in shares of AstraZeneca during the fourth quarter worth $27,000. Pathway Financial Advisers LLC purchased a new position in shares of AstraZeneca during the first quarter worth $29,000. Hobbs Group Advisors LLC purchased a new position in shares of AstraZeneca during the second quarter worth $35,000. Finally, Pin Oak Investment Advisors Inc. raised its holdings in shares of AstraZeneca by 468.4% during the fourth quarter. Pin Oak Investment Advisors Inc. now owns 449 shares of the company’s stock worth $30,000 after purchasing an additional 370 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Stock Down 0.3 %

Shares of NASDAQ:AZN traded down $0.26 during trading hours on Tuesday, reaching $76.61. The stock had a trading volume of 776,834 shares, compared to its average volume of 5,160,846. AstraZeneca PLC has a 1 year low of $60.47 and a 1 year high of $87.68. The firm’s 50 day moving average is $81.59 and its 200-day moving average is $77.60. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89. The stock has a market capitalization of $237.53 billion, a price-to-earnings ratio of 37.68, a P/E/G ratio of 1.43 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Thursday, July 25th. The company reported $0.99 EPS for the quarter, beating analysts’ consensus estimates of $0.98 by $0.01. AstraZeneca had a net margin of 13.11% and a return on equity of 29.34%. The company had revenue of $12.45 billion for the quarter, compared to the consensus estimate of $12.62 billion. During the same period in the prior year, the firm posted $1.08 EPS. The company’s quarterly revenue was up 9.1% compared to the same quarter last year. Research analysts predict that AstraZeneca PLC will post 4.08 earnings per share for the current fiscal year.

AstraZeneca Cuts Dividend

The business also recently announced a Semi-Annual dividend, which was paid on Monday, September 9th. Stockholders of record on Friday, August 9th were issued a $0.49 dividend. This represents a dividend yield of 1.8%. The ex-dividend date was Friday, August 9th. AstraZeneca’s payout ratio is 48.04%.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Barclays raised shares of AstraZeneca to a “strong-buy” rating in a report on Monday, June 24th. Citigroup raised shares of AstraZeneca to a “strong-buy” rating in a report on Monday, June 24th. Deutsche Bank Aktiengesellschaft cut shares of AstraZeneca from a “hold” rating to a “sell” rating in a report on Friday, September 13th. Finally, TD Cowen lifted their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.